OSE Immunotherapeutics Presented Preclinical Results at AACR Congress

OSE Immunotherapeutics, a French biotechnology company, presented new preclinical data regarding its SIRPa antibody at the American Association for Cancer Research (AACR) congress. The presented information pertained to the efficacy of the SIRPa antibody in treating cancerous tumors. SIRPa (signal regulatory protein alpha) is a protein involved in regulating the immune system, and its inhibition may enhance the recognition and destruction of cancer cells.

The poster shared at the congress detailed how a combination of the SIRPa antibody and other immunotherapy drugs could improve treatment responses in certain cancer types. The research is still in its early stages, and further studies are needed to confirm its clinical potential.

OSE Immunotherapeutics focuses on developing treatments for oncology and autoimmune diseases using biologic drugs. The company has several novel therapies in various stages of development. The company's next step is to evaluate the safety and efficacy of the SIRPa antibody in clinical trials.